about
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyLate Ebola virus relapse causing meningoencephalitis: a case reportCharacteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participantsTreatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Acute renal failure complicating HELLP syndrome, SLE and anti-phospholipid syndrome: successful outcome using plasma exchange therapy.MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritisIdentification of urinary peptide biomarkers associated with rheumatoid arthritis.Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritisFunctionally optimized orthoses for early rheumatoid arthritis foot disease: a study of mechanisms and patient experience.The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobankRheumatological complications of sickle cell disease.Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers.Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups.Pharmacotherapy: concepts of pathogenesis and emerging treatments. Optimising the strategy of care in early rheumatoid arthritis.Brief Report: Predicting Functional Disability: One-Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort.Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.The 'natural' history of active rheumatoid arthritis over 3-6 months--an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo.Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.Oxygen cost of walking, physical activity, and sedentary behaviours in rheumatoid arthritis.2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis.The RA-MAP Consortium: a working model for academia-industry collaboration.Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.Time for treatment targets in rheumatoid arthritisEditorial: Choosing New Targets for Rheumatoid Arthritis Therapeutics: Too Interesting to Fail?DAS28 and Rheumatoid Arthritis: The Need for StandardizationTrials in rheumatoid arthritis: choosing the right outcome measures--comment on the article by Felson et alUK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drugMyocrisin-mediated oxidative stressPNEUMOCYSTIS CARINII INFECTION COMPLICATING CYTOTOXIC THERAPY IN TWO PATIENTS WITH LYMPHOPENIA, BUT A NORMAL TOTAL WHITE CELL COUNT
P50
Q24674942-EBF3812B-10A8-4D4D-A3B0-DDA93AF776E7Q28385572-42717433-D5DF-4856-951D-FF4E3CAB44C6Q28596816-C64F1C7F-4E71-4340-8CB1-B8B5800DCACCQ30680371-A080D945-9B97-46FF-9B25-3F3A60F417BFQ30790635-D78F325C-CA4F-4115-A866-2FFC5A41F7FFQ33849824-14C33929-3FAB-4054-871C-43755CD0214AQ34075303-D34AD89D-8B9E-4A03-AD8F-55EF23304007Q34317197-B2C6552A-7358-4386-9854-1015E77A5667Q34803070-FE995E1A-E045-4D52-83D3-E3B11EAFF823Q36187856-84F3F7A5-181B-4E03-8FF0-47FA965AADC1Q36848326-31955164-D4DD-4F46-8A07-F2781E3A0359Q37338261-8F9AF900-C360-413A-9EA1-50348EF7E466Q37657244-AF24598F-EAF1-44AA-896E-D6AD6F7CEC9DQ37781911-085D16BA-D1C0-41A6-A1E4-8414732F6360Q40005234-A28626AB-3AD6-4F18-8595-70B1EAEC6B4EQ40736371-F3139AA9-7C39-40A9-9165-FC24B62BA90AQ41076785-094A9BFD-B8A3-45B4-AF85-3E7C913EB643Q44985061-72988155-8D42-4433-851D-7E4640769B32Q46889098-F69DAAFF-051C-4813-AA69-B0DF67295A2FQ47208181-D214E349-5F57-4E06-9180-2D0EA8139582Q47355032-2C835571-F44C-45D0-B382-946B849298D8Q47793490-1E6EE881-89FD-4422-BB56-96BD07603383Q49838635-7B8FEE7D-8EB1-4870-936E-24044E3B3795Q50851551-4F6E1BDF-64E0-4564-955C-B25655C74B04Q57231994-F68CDCD8-35E5-43A5-A88E-8EA29AB0656AQ61628441-930F7C0D-1E6C-4870-9DB3-1FDBB0B74B3CQ61628443-E3AA2816-C9E7-45CE-B94F-E20788DA07B2Q61628444-0D19835F-785A-433B-81C8-90D6D104FFC6Q61628446-81376A34-CA1E-40EF-BC79-76EFB368053FQ61628448-FBA15E58-ACEF-46CE-B63B-03DE5A7DFAB1Q61628450-90AAADD3-15BD-4623-AA14-2E0A750719F4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Duncan Porter
@ast
Duncan Porter
@en
Duncan Porter
@es
Duncan Porter
@nl
Duncan Porter
@sl
type
label
Duncan Porter
@ast
Duncan Porter
@en
Duncan Porter
@es
Duncan Porter
@nl
Duncan Porter
@sl
prefLabel
Duncan Porter
@ast
Duncan Porter
@en
Duncan Porter
@es
Duncan Porter
@nl
Duncan Porter
@sl
P106
P1153
7401830543
P21
P31
P496
0000-0001-8481-5204